The unique physiological and morphological properties of neuronal populations are crucial for the appropriate functioning of neuronal circuits. Alternative splicing represents an attractive mechanism for generating cell type-specific molecular repertoires that steer neuronal development and function. However, the mechanisms that link neuronal identity to alternative splicing programs are poorly understood. We report that cell type-specific, mutually exclusive expression of two alternative splicing regulators, SLM1 and SLM2, in the mouse hippocampus is achieved by a cross-repression mechanism. Deletion of SLM2 in vivo modifies alternative splicing of its paralog Slm1 and stabilizes its mRNA, resulting in expression of SLM1 in previously SLM2-expressing cells. Despite this ectopic upregulation of SLM1, loss of SLM2 severely disrupts the alternative splicing regulation of Nrxn1, Nrxn2, and Nrxn3, highlighting that the two SLM paralogs have partially divergent functions. Our study uncovers a hierarchical, SLM2-dependent mechanism for establishing cell typespecific expression of neuronal splicing regulators in vivo.
Introduction
The mammalian nervous system consists of a complex network of neuronal cell types, which are defined by unique molecular, physiological, and anatomical properties. Cell type-specific properties rely on gene expression programs that shape protein levels and isoform repertoires, including cell surface receptors, ion channels, signaling, and transport regulators. The transcriptional mechanisms that specify neuronal cell types and guide their growth during early development have been extensively studied (Dasen and Jessell, 2009; Hobert et al., 2010) . By comparison, there is a lack of knowledge about cell type-specific gene expression programs associated with neuronal connectivity and function, in particular with respect to the complex recognition events between synaptic partners.
Significant diversification of protein function is achieved at the level of alternative pre-mRNA splicing (Norris and Calarco, 2012; Darnell, 2013; Zheng and Black, 2013) . Temporally and spatially controlled alternative splicing programs can direct molecular and, thereby, functional diversity of gene products. More recently, alternative splicing-dependent nonsense-mediated mRNA decay (NMD) has emerged as a mechanism for controlling gene expression levels (McGlincy and Smith, 2008; Bicknell et al., 2012) . To this end, alternative splicing directs the incorporation of exons, which contain premature translation termination codons, leading to the targeted degradation of the mRNA. Thus, alternative splicing not only contributes to the molecular diversification of gene products but also plays a major role in the regulation of levels and kinetics of protein expression.
A prerequisite for cell type-specific gene regulation through alternative splicing is the selective expression of alternative splicing regulators in defined cell populations. One interesting example are the KH-domain containing RNA-binding proteins Sam68, SLM1, and SLM2 (Sam68-like mammalian proteins), which belong to the STAR (signal transduction and activator of RNA) family. SAM68 (Src-associated substrate in mitosis of 68 kDa) is ubiquitously expressed in neuronal and non-neuronal cells, whereas SLM1 and SLM2 exhibit a remarkable, mutually exclusive expression in neuronal cell types (Di Fruscio et al., 1999; Venables et al., 1999; Stoss et al., 2004; Iijima et al., 2011 Iijima et al., , 2014 . Notably, SLM1 and SLM2 are important regulators of neuron-specific alternative splicing, as both proteins repress incorporation of alternative exons at the alternatively spliced segment 4 (AS4) in Nrxn1, Nrxn2, and Nrxn3, a class of synaptic cell surface receptors (Iijima et al., 2011 (Iijima et al., , 2014 Ehrmann et al., 2013 Aoto et al., 2013) . Despite this critical importance of SLM1 and SLM2 function in generating cell type-specific repertoires of NRX iso-forms, the mechanisms underlying the mutually exclusive expression of SLM1 and SLM2 proteins in the mammalian nervous system are unknown.
In this work, we uncover that deletion of Slm2 in mice results in an unexpected elevation of SLM1 expression, specifically in cells formerly expressing SLM2. In wild-type but not Slm2 KO neurons, Slm1 mRNA is targeted for NMD by use of a previously uncharacterized splice donor site in the 3ЈUTR. Ectopic expression of Slm2 in dentate granule cells of the hippocampus is sufficient to suppress endogenous SLM1 expression. Surprisingly, deletion of Slm2 alone results in a profound disruption in alternative splicing regulation of Nrxn1, Nrxn2, and Nrxn3, despite the upregulation of Slm1. Our study highlights a key function for Slm2 in neuronal alternative splicing regulation by directing cell type-specific splice variant choices of Nrxns. Moreover, our results provide strong genetic evidence for alternative splicing coupled NMD in instructing cell type-specific gene expression patterns in vivo.
Materials and Methods
Knock-out mice. Slm1 KO mice were previously described (Iijima et al., 2014 ). An Slm2 conditional allele was generated by homologous recombination in mouse embryonic stem cells. Briefly, a genomic DNA fragment containing exon 2 (ENSMUSE00000328887) was flanked by a LoxP site and a FRT-PGK-neo-LoxP cassette encoding neomycin phosphotransferase under the control of the phosphoglycerate kinase 1 promoter. The targeting vector was electroporated into 129SvEvTac embryonic stem cells. Homologous recombination in G-418-resistant clones was confirmed, and selected cells were blastocyst injected. Chimeric animals were crossed with ROSA-26 Flpe mice (Farley et al., 2000) to remove PGK-neo sequences through Frt/Flp-mediated excision. Slm2 flox/ϩ mice were crossed with CMV cre deleter mice (Schwenk et al., 1995) to create a germline deletion of exon 2. The Slm2 flox allele was detected by PCR using primers 5Ј-GCTTTACAGTAGAGAAACTGG-3Ј (Lox gtF), 5Ј-CATAGATGACCTGCTGTCAG-3Ј (Lox gtR), 5Ј-CGGTTGGATGG-TATACATGAC-3Ј (Frt gtF), and 5Ј-CAATGCTGTTACTCATCAGG-3Ј (Frt gtR). Slm1:Slm2 DKO mice were generated by intercrossing of the individual mutant mice. The resulting homozygous mice were viable.
Antibodies. Polyclonal antibodies for SAM68, SLM1, and SLM2 were previously described (Iijima et al., 2014) . Commercially available antibodies were used: mouse anti-␤-tubulin (E7, DSHB, 1:10000), mouse anti-GFP (Invitrogen, 1:1000), and mouse anti-NeuN (Millipore Bioscience Research Reagents, 1:2000). Molecular biology procedures. For immunoblotting, either HRPconjugated secondary antibodies and Pierce ECL Western Blotting Substrate or fluorescent IRDye coupled secondaries were used. Signals were acquired using an image analyzer (Bio-Rad, ChemiDoc MP Imaging System and Li-Cor, Odyssey). Dissociated cultures of mouse hippocampal cells were prepared from P0 pups and maintained in Neurobasal medium (Invitrogen ) containing 2% B27 (Invitrogen) supplement and 2 mM Glutamax (Invitrogen) at 37°C and 5% CO 2 . Cylcoheximide was applied at a final concentration of 50 g/ml for 4 h before harvesting. Total RNA from cultured cells was extracted with Trizol and purified using QIAGEN RNeasy Mini Kit.
Alternative splicing analysis. PCR primer sequences are as follows: Nrxn1 AS4, 5Ј-TGTTGGGACAGATGACATCGCC-3Ј and 5Ј-GAGAGCTGGCCCTGGAAGGG-3Ј; Nrxn2 AS4, 5ЈGTGCGCTT-TACTCGAAGTGGTG3Ј and 5ЈCCCATTGTAGTAGAGGCCGGAC3Ј; Nrxn3 AS4, 5ЈTTGTGCGCTTCACCAGGAATG3Ј and 5ЈAGAGCCCA-GAGAGTTGACCTTG3Ј; Gapdh, 5ЈGCTTGTCATCAACGGGAAG3Ј and 5ЈTTGTCATATTTCTCGTGGTTCA3Ј; and Slm1 Ex8-Ex9b, 5ЈCTACGGTCATGGAGTAAACGAG3Ј and 5Ј GGGAATACAA-GAAATAGTGGGAGC3Ј; and Slm1 Ex8-Ex10, 5ЈCTACGGTCATG-GAGTAAACGAG3 and 5ЈCCCTTTAGGCCATCATATCTGC3Ј.
Sequences of quantitative PCR primers. Quantitative PCR was performed on a StepOnePlus qPCR system (Applied Biosystems). Gene expression assays were used with TaqMan Master Mix (Applied Biosystems) or Power SYBR Green Master Mix (Applied Biosystems) and comparative C T method. The cDNA levels were normalized to Gapdh cDNA.
Commercially available gene expression assays for Gapdh (Mm99999915g1), Nrxn1 (Mm00660298_m1), Nrxn2 (Mm01236851_ m1), and Nrxn3 (Mm00553213_m1) were from Applied Biosystems; and assays for Slm1 (Mm.PT.58.41510930) and Slm2 (Mm.PT.58.10822025) were from Integrated DNA Technologies. Custom gene expression assays to interrogate Nrxn splicing at AS4 were previously described (Iijima et al., 2014) .
Primer sequences used with Power SYBR Green PCR Mastermix were as follows: Slm1 Ex3-Ex4, 5Ј-GACCAAGAGGAAACTCCTTGAA-3Ј and 5Ј-GGCATGACTCATCCGTGAATA-3; Slm1 Ex8-9a, 5Ј-GTGCCT-GAATACTATGACTACGG-3Ј and 5Ј-GAGACCACAGGCTATGAA TTGT3Ј; Slm1 Ex9a-9b, 5Ј-CATCTGTGACCTCCTCAAAGAC-3Ј and 5Ј-TGTCCACGTCACATTAACAGTAT-3Ј; and Slm1 Ex9a-10, 5Ј-CATCTGTGACCTCCTCAAAGAC-3Ј and 5Ј-CCCTTTAGGCCAT CATATCTGC-3Ј.
Immunohistochemistry, image acquisition, and statistical analysis. Animals (male and female) were transcardially perfused with fixative (4% PFA/15% picric acid in 100 mM phosphate buffer, pH 7.2). Tissue was sectioned at 50 m in PBS on a vibratome (VT1000S, Leica), and floating sections were immunostained following standard procedures. Images were acquired at room temperature on an inverted LSM700 confocal microscope (Zeiss) using 10ϫ and 63ϫ Apochromat objectives and controlled by Zen 2010 software. Images were assembled using Adobe Photoshop and Illustrator software. For quantitative assessment of protein upregulation or downregulation, ImageJ was used. Statistical analysis was done with Prism software (GraphPad software). All statistical data are mean Ϯ SEM. Data were tested for normality using ANOVA and Bonferroni's or Dunnett's post hoc test for multiple comparisons.
All procedures related to animal experimentation were reviewed and approved by the Kantonales Veterinäramt Basel-Stadt.
Adeno-associated virus (AAV) production. Viral supernatants were produced by cotransfection of HEK293T cells with a mixture of three plasmids. The plasmid mixture consisted of 70 g of AAV helper plasmid (Rep/Cap, Serotype II), 200 g of AAV pHGTI-adeno1 (Plasmid Factory), and 70 g of vector plasmid Synapsin-SLM2-2A-Venus or Synapsin-EGFP (containing the human synapsin promoter). At 45-60 h after transfection, medium containing viral particles was harvested and purified using the Iodixanol purification method. The fraction samples were dialyzed and concentrated in Millipore Amicon 100K columns, washed 3ϫ with PBS, and centrifuged at 3500 rpm at 4°C. Viruses were frozen in aliquots and stored at Ϫ80°C. Viruses were delivered by stereotaxic injection at postnatal day 8 into the dentate gyrus (DG) of the mouse hippocampus. Infected cells were marked by EGFP expression from the same vector. Animals were transcardially perfused at postnatal day 40, and 50-m-thick vibratome slices were analyzed by immunohistochemistry. 
Results

Ablation of Slm2 in vivo results in elevated expression of Slm1
To explore functions of the RNA-binding protein SLM2 in vivo, a novel mouse knock-out Slm2 allele was created in which exon2 of the mouse Khdrbs3 gene (which encodes for SLM2) was flanked by LoxP sites. Global Slm2 KO mice were generated by cremediated recombination in the germline. Removal of exon 2 introduces multiple premature stop codons and disrupts the Slm2 open reading frame (Fig. 1A) . SLM2 is mainly expressed in the brain and in testis (Stoss et al., 2004; Venables et al., 2004) ; we thus investigated loss of SLM2 in these body regions (Fig. 1B) . Additionally, Western blotting analysis with two SLM2-specific antibodies directed against different epitopes further confirmed that Slm2 KO mice lacked detectable SLM2 protein expression (Fig. 1C) . Slm2 KO mice were viable and fertile and did not exhibit obvious behavioral abnormalities, as previously reported for a different Slm2 KO allele (Ehrmann et al., 2013) .
Upregulation of SLM1 in previously SLM2-positive cells
Surprisingly, we detected a 2.5-fold upregulation of SLM1 protein levels in hippocampus and cortex of Slm2 KO mice (Figure 2A ; one-way ANOVA with Bonferroni post hoc test, p Ͻ 0.01). A significant increase was also detected for Slm1 mRNA in the hippocampus of Slm2 KO mice ( Fig. 2B ; one-way ANOVA with Bonferroni post hoc test, p Ͻ 0.01). By contrast, no alterations were observed for the closely related RNA-binding protein SAM68 (data not shown). To explore whether SLM1 is globally elevated or whether its upregulation is restricted to specific cell populations, we performed detailed immunohistochemical analysis using SLM1-and SLM2-specific antibodies. Principal cells in the mature hippocampus exhibit a remarkable, cell type-specific expression pattern of SLM1 and SLM2: SLM1 is expressed in dentate granule cells, and a specific subgroup of inhibitory interneurons, however, is absent from the cornus ammonis-1 (CA1) and CA3 pyramidal cells. By contrast, SLM2 is highly expressed in the CA1 and CA3 pyramidal cells and a different set of interneurons, but not detectable in the DG (Stoss et al., 2004; Iijima et al., 2014) (Fig. 3A, top) . In Slm2 KO mice, SLM1 was significantly upregulated in CA1 and CA3, whereas expression in DG was unchanged (Fig. 3 A, B ; two-way ANOVA with Bonferroni post hoc test). Thus, in the absence of SLM2, formerly SLM2-positive cells selectively turn on SLM1 expression. This suggests that the mutually exclusive expression pattern of SLM1 and SLM2 in neuronal populations might be achieved through cross-repression of SLM1 by SLM2. Interestingly, we did not detect an analogous upregulation of SLM2 in the DG of Slm1 KO mice (Fig. 3 A, B) . These findings suggest that SLM2 is required for spatially restricting SLM1 expression in a unidirectional manner.
Slm2 is required and sufficient to establish the mutually exclusive expression pattern of SLM proteins
Considering that SLM2 is an RNA-binding protein, we hypothesized that it may suppress Slm1 expression by targeting Slm1 mRNA for NMD in wild-type animals. To test this possibility, we treated cultured wild-type and Slm2 KO hippocampal neurons with cycloheximide (CHX), an inhibitor of protein translation. As NMD depends on active translation, transcripts that are subject to NMD are stabilized upon translational arrest (Carter et al., 1995) . Slm1 transcript levels increased threefold upon CHX treatment of wild-type neurons. (Fig. 4A ; one-way ANOVA with Bonferroni post hoc test). Importantly, in Slm2 KO cultures, Slm1 transcript levels were not further increased after CHX treatment ( Fig. 4A ; one-way ANOVA with Bonferroni post hoc test, not significant, p Ͼ 0.05).
In the same experiment, CHX treatment appears to slightly elevate Slm2 transcripts in wild-type and Slm2 KO neurons (Fig.  4A) , although this trend did not reach statistical significance.
These findings are consistent with NMD of Slm1 mRNA through a process that requires Slm2. One possible mechanism of how SLM2 could target Slm1 mRNA for NMD would be the incorporation of alternative exon sequences through regulated alternative splicing that attract exon junction complexes downstream of the stop codon in Slm1 transcripts. Through database searches, we identified a previously uncharacterized potential splice donor site in exon9 of Slm1, which would link two additional exons encoding the 3ЈUTR (exons 10 and 11; Fig. 4B ). We hypothesized that an SLM2-driven alternative splicing event might promote incorporation of these exons. To test this possibility, we performed exon-spanning RT-PCRs for the presumptive exon 10 in the 3Ј UTR. We used primer sets binding upstream and downstream of the potential internal splice donor site flanking various exons of the Slm1 transcript (Fig. 4B) . We could confirm the novel transcript 2 variant linking exon 8 and exon 10 (PCR products exons 8 -10), representing the Slm1 variant containing a 3Ј UTR intron, predicted to undergo NMD (Fig.  4D) . In Slm2 KO mice, we observed an increase in the alternative transcript 1 variant containing exon 8 -9b both with RT-PCR and quantitative RT-PCR, confirming that the presence of SLM2 suppresses formation of this (stable) form of Slm1 mRNA (Fig. 4C,D ; Dunnett's multiple comparison test). Using primer pairs upstream of the internal splice donor site (exons 3 and 4, exons 8 and 9a), we further confirmed that the whole Slm1 transcript was stabilized (Fig. 4C) . Products containing exons 8 -10 showed a trend to decrease in Slm2 KO cells (Fig. 4C) . However, if these mRNAs are indeed targeted for translation-dependent decay, this is difficult to quantify. To further explore this possibility, we performed CHX treatment of wild-type hippocampal neurons. Exons 8 -10-containing transcripts were significantly increased in CHX-treated cells, consistent with the hypothesis that they are targeted for NMD (Fig. 4E) .
If Slm2 indeed targets Slm1 mRNA for degradation, then Slm2 should be sufficient to suppress SLM1 expression when introduced into SLM1-positive cell populations. AAV-mediated SLM2 mis-expression in the DG of the mouse hippocampus in vivo abolished SLM1 expression in dentate granule cells (Fig.  5 A, B) . SLM2 was introduced into the DG at postnatal day 8 (P8), and mis-expressing neurons were viable and developed apparently normal axonal and dendritic processes when analyzed at P40. However, their cell nuclei were devoid of SLM1 protein. Thus, SLM2 is required and sufficient to regulate the cell typespecific expression of SLM proteins in vivo.
Alternative splicing regulation in Slm1:Slm2 DKO mice SLM1 and SLM2 have partially overlapping targets; however, they are expressed in largely nonoverlapping cell populations (Stoss et al., 2004; Iijima et al., 2014) . Thus, the upregulation of SLM1 in Slm2 KO neurons needs to be considered when interpreting loss-of-function phenotypes. We set out to determine the impact of Slm1 and Slm2 loss-of-function in Slm1:Slm2 DKO mice. Slm1:Slm2 DKO mice were born at Mendelian frequencies and were viable. Successful ablation of SLM1 and SLM2 was verified by immunohistochemistry ( Fig. 6A) and Western blotting analysis (Fig. 6B) . Slm1 KO as well as Slm2 KO neurons fail to direct exon skipping of Nrxn1-3 at AS4, which correlates with their regional expression in the brain (Ehrmann et al., 2013 , Iijima et al., 2014 KO cortex and hippocampus remained unchanged (Fig. 6C,D) . Quantitative RT-PCR revealed that overall Nrxn1, Nrxn2, and Nrxn3 levels were unaltered in all three mutants and confirmed a striking increase of AS4(ϩ) in Nrxn1-3 for the Slm2 KO and the Slm1:Slm2 DKO ( Fig. 6D ; two-way ANOVA). Notably, there was a significant loss of Nrxn AS4-splice isoforms in Slm2 KO hippocampus, despite the substantial upregulation of SLM1 in SLM2-deficient cells. Thus, in vivo, SLM1 upregulation cannot significantly compensate for loss of SLM2, at least with respect to alternative splicing regulation of Nrxns at AS4.
Discussion
In mammals, regulated alternative splicing events are widespread; however, the factors underlying the generation of neuronal cell type-specific alternative patterns are poorly understood.
The ability of alternative splicing to generate mRNA isoforms that are targeted for NMD extends the functional impact of alternative splicing regulation from the generation of multiple isoforms derived from a single gene to the spatial and temporal control of transcript levels. In this study, we set out to uncover in vivo functions of SLM2 in neurons and identified an unexpected role in setting up the mutually exclusive expression of SLM1 and SLM2 paralogs in neuronal cell types.
We observed that SLM2 itself is required and sufficient for the mututally exclusive expression of SLM1 and SLM2 in genetically and anatomically defined populations of neurons in the mouse hippocampus. SLM2 promotes the incorporation of an alternative splice donor in the last coding exon of the Slm1 transcript. Notably, transcripts with 3ЈUTR introns have long been considered to be erroneous predictions as the resulting mRNAs would be predicted to be NMD substrates. However, recent studies have highlighted unexpected functions of some of these transcripts (Bicknell et al., 2012) . We identified one such transcript containing a 3ЈUTR intron for Slm1. Our genetic gain-and loss-offunction analysis in mice demonstrates that this mRNA is indeed produced through SLM2-dependent alternative splicing and that the resulting destabilization of the alternative Slm1 transcript represents a fundamental mechanism underlying the neuronal cell type-specific expression of SLM1 protein in vivo.
Previous studies performed largely in cell lines demonstrated that splicing regulators are able to control their own expression by producing splice isoforms of their own mRNA that are targeted for NMD (Lareau et al., 2007; Ni et al., 2007) . Further studies identified cross-regulation between paralogs of alternative splicing regulators, such as PTBP1 (polypyrimidine-tractbinding protein 1) and PTBP2 (Boutz et al., 2007; Spellman et al., 2007) , to shift the alternative splicing patterns from precursors to postmitotic neurons during differentiation and maturation in development. Our results identify a similar cross-repression mechanism for SLM1 and SLM2 to generate a highly spatially restricted pattern of SLM paralogs in specific neuronal populations. SAM68, SLM1, and SLM2 bind similar RNA sequence motifs (Galarneau and Richard, 2009 ) and appear to regulate some common targets. However, these proteins also exhibit certain isoform-specific properties, including differential regulation by kinases and selective association with additional alternative splicing factors, which results in differential splicing activities (Stoss et al., 2004; Iijima et al., 2011 Iijima et al., , 2014 . Thus, SAM68 requires activation through calcium/CaMK4 signaling to modify alternative splice isoform choices of Nrxns, whereas SLM1 and SLM2 seem to be constitutively active in a cell type-specific manner. In the midbrain, where SLM1 is highly expressed, Nrxn alternative splicing at AS4 is significantly altered in Slm1 KO mice (Iijima et al., 2014) . By contrast, in the hippocampus where SLM1 protein levels are lower, its deletion has little impact on Nrxn1, Nrxn2, and Nrxn3 AS4 regulation. Possible explanations of why neither SAM68 nor SLM1 rescued the splicing phenotype observed in Slm2 KO cells include that these cells lack signaling-dependent activation or cofactors for SAM68 or SLM1 function, respectively.
Our work uncovers a mechanism underlying the mutually exclusive, cell type-specific expression pattern of STAR proteins in the mammalian brain. Loss of Slm2 function results in the production of Nrxn variants with altered affinity for their synaptic binding partners (Boucard et al., 2005; Chih et al., 2006; Baudouin and Scheiffele, 2010; Uemura et al., 2010) . Further studies will be needed to determine the impact of Slm2-dependent alternative splicing with regards to changes in synaptic connectivity.
